Report updated Apr 24, 2026
FlashRX - Top 250 Drugs
For healthcare students and professionals, including pharmacists, nurses, and medical students preparing for standardized exams like the NAPLEX or USMLE.
Overview · Full Intel report in progress
FlashRX - Top 250 Drugs is an established medical app that is a paid app. With a 3.6/5 rating from 25 reviews, it shows polarized user reception.
What makes this app unique?
What Does It Look Like?
What Are The Key Features?
Provides an intuitive interface for reviewing drug information to build a core knowledge base.
Offers a testing environment to reinforce memorization of the top 250 medications.
Allows users to practice specific drugs that require more focus based on user performance.
Enables users to add specific drugs to the existing database for personalized study sessions.
How much does it cost?
Who Built It?
ClinCalc
Providing evidence-based clinical decision support and pharmacology education tools for healthcare professionals and students.
Portfolio
5
Apps
What other apps does ClinCalc make?
Explore the full ClinCalc report
Portfolio breakdown, audience, momentum, and every app published by ClinCalc.
Analysis in progress, available soon
What do users think recently?
Analysis in progress, available soon
View the full user-sentiment analysis
Mood gauge, ratings & review-volume history, every praise / complaint / request, and sentiment over time.
Analysis in progress, available soon
What is the competitive landscape for FlashRX - Top 250 Drugs?
Where is it available?
Localized markets (1)
How's The Medical Market?
How does it evolve in the Medical market?
Rank progression
3 active rankings tracked — 30-day window
Strategic analysis coming soon
SWOT, key takeaways & outlook
The outtake for FlashRX - Top 250 Drugs
Key Takeaways
While marketed as a focused study aid, user feedback highlights concerns regarding content depth, audio quality, and the app's competitiveness against free or more comprehensive alternatives.
Where Is It Heading?
Trend analysis
Available very soon